07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

CDX-014: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial to evaluate CDX-014 every 3 weeks in about 47 patients with clear cell or papillary RCC and progressed disease after >=2 prior therapies, including 1 VEGF-targeted tyrosine...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Celldex preclinical data

In mouse xenograft models of ovarian cancer and RCC, 75, 150 and 300 µg intraperitoneal injections of CDX-014 on days 0, 4, 8 and 12 each significantly improved percent survival vs. saline-treated controls (p<0.05 for...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Organ transplant rejection T cell immunoglobulin and mucin domain 1 (HAVCR1; TIM-1) Studies in mice suggest TIM-1 antibodies could help prevent transplant rejection. In a...
07:00 , May 19, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Ebola T cell immunoglobulin and mucin domain 1 (HAVCR1; TIM-1) In vitro studies suggest blocking TIM-1 could help treat Ebola...
07:00 , Jul 22, 2010 |  BC Innovations  |  Targets & Mechanisms

Something against TIM-1 in asthma

Researchers at Biogen Idec Inc. and colleagues have used a humanized mouse model to show that inhibiting T cell immunoglobulin and mucin domain 1 could help treat allergic asthma. 1 The findings are the first...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Company News

CuraGen cancer news

CuraGen retained JSB-Partners to identify potential buyers for CuraGen's lead candidate CR011-vcMMAE and plans to retain an investment bank to review other alternatives, including acquisitions or a sale of the company. CR011-vcMMAE, a human mAb...